Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 2/20 | 0.74 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | PSD | A5PKW4 | 9/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11642434 | 0.84 | RAD51 (0.73) | RAD51KDM5BMAPTALDH1A1LOXL2 | |
| SCHEMBL7711852 | 0.70 | RAD51 (0.62) | RAD51KDM5BMAPTALDH1A1LOXL2 | |
| SCHEMBL11641077 | 0.70 | KDM5B (0.46) | RAD51KDM5BMAPTALDH1A1MCL1 | |
| SCHEMBL8105987 | 0.70 | NPC1 (0.55) | KDM5BMAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL8100226 | 0.68 | KDM4E (0.59) | RAD51KDM5BMAPTALDH1A1PSD | |
| SCHEMBL8108178 | 0.68 | NPC1 (0.47) | RAD51KDM5BMAPTALDH1A1MCL1 | |
| SCHEMBL8099805 | 0.68 | NPC1 (0.58) | RAD51MAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL1661596 | 0.68 | KDM5B (0.44) | KDM5BMAPTALDH1A1MCL1PSD | |
| SCHEMBL8101357 | 0.68 | HTT (0.49) | RAD51KDM5BMAPTALDH1A1MCL1 | |
| SCHEMBL7716579 | 0.67 | LOXL2 (0.54) | RAD51KDM5BALDH1A1LOXL2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | RAD51 3582/4885KDM5B 2918/4885MAPT 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.